NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy - Gilde Healthcare

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

December 22, 2017

The Hague, the Netherlands – NightBalance, a leader in innovative obstructive sleep apnea therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Sleep Position Trainer (SPT®), developed by NightBalance, treats Positional Obstructive Sleep Apnea (POSA) which affects half a million people in the Netherlands. The Dutch Ministry of Health, Welfare and Sport will formally approve inclusion of the SPT® following ZIN’s recommendation.

The approval is based on the company’s strong data, demonstrating clinical efficacy, which allowed NightBalance to successfully fulfil the high standards set by the reimbursement approval process in the Netherlands for new medical devices and therapeutics. The government’s decision allows health care insurers in the Netherlands to offer all Dutch citizens suffering from POSA the SPT® device as part of the basic insurance plan.

The ZIN approval is the recognition of ground-breaking work in building a solid clinical data set of more than 80,000 nights in peer reviewed published research, demonstrating the ease of use, efficacy, and cost-effectiveness of our therapy and the SPT® device. The SPT® offers a user-friendly alternative to current treatments with more convenience and comfort for the patient and less cost for the healthcare system.

 

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund.
Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America.
Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the...
June 10, 2022

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022